Maria Sklodowska-Curie National Research Institute of Oncology

Evaluation of the Safety and Efficacy of Mifamurtide Versus Standard Treatment With Sorafenib in Patients With High-risk Osteosarcoma

Collaborator, Phase 2, Recruiting, 2026, 40 people, 26 Aug 2026, clinicaltrials.gov

NCT05271162

Phase 3, Active, not recruiting, 2023, 220 people, 8 Mar 2022, clinicaltrials.gov

NCT01549418

Phase 4, Status unknown, 2012, 760 people, 9 Mar 2012, clinicaltrials.gov